- Chimeric Antigen Receptor (CAR) T-cell therapy
- Tumor-Infiltrating Lymphocyte (TIL) therapy
- In Vitro Sensitized (IVS) T-cell therapy
- T-Cell Receptor Therapy
Thanks to our strong research program and pioneering early-phase clinical trials program, we can provide the types of treatments offered only in the nation’s top cancer centers. In 2017 Roswell Park became the first center in the world to use a two-gene combination for adoptive T-cell therapy.
We are also authorized to provide the CAR T-cell therapies Yescarta and Kymriah, the only FDA-approved cellular therapies. These may be options for patients who are not eligible for blood or marrow transplant, or may serve as a “bridge” to manage the disease until transplant is possible.